New hope for cancer pain: drug combo aims to cut suffering
NCT ID NCT05265052
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a new drug (3D1002) to a standard painkiller (oxycodone) can better control moderate to severe cancer pain. About 177 adults with cancer and ongoing pain will receive either the combination or standard treatment. The goal is to see if the new approach reduces pain intensity and limits breakthrough pain episodes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden risk: could opioid misuse be overlooked in cancer care?
- Could common painkillers boost opioid effectiveness for cancer patients?
- New Low-Dose pain patch aims to ease cancer suffering
- Radiosurgery zaps cancer pain when opioids fail
- Can video calls replace clinic visits for cancer pain?
- Massage therapy may ease painful sex after gynecological cancer